Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus

References

• Zuo H, Shi Z, Hussain A. Prevalence, trends and risk factors for the diabetes epidemic in China: a systematic review and meta-analysis. Diabetes Res Clin Pract 2014;104:63-72
   PubMed Web of Science ®Google Scholar
• Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care 1997;20:1664-9
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
   PubMed Web of Science ®Google Scholar
• WHO. Noncommunicable Disease (NCD) Country Profile China 2014. 2014. Available at: http://www.who.int/nmh/countries/chn_en.pdf April 2, 2016
   Google Scholar
• Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2013;381:1987-2015
   PubMed Web of Science ®Google Scholar
• Wang W, McGreevey WP, Fu C. Type 2 diabetes mellitus in China: a preventable economic burden. Am J Manag Care 2009;15:593-601
   PubMed Web of Science ®Google Scholar
• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2224-60
   Web of Science ®Google Scholar
• Lane S, Levy AR, Mukherjee J. Overweight and obesity (high body mass index). Comparative quantification of health risks: global and regional burden of disease attribution to selected major risk factors 2004;1:497-596
   Google Scholar
• Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-59
   PubMed Web of Science ®Google Scholar
• Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9
   PubMed Web of Science ®Google Scholar
• Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Medicinal Chemistry 2008;51:1145-9
   PubMed Web of Science ®Google Scholar
• Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82
   PubMed Web of Science ®Google Scholar
• Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Investigation 1994;93:397
   PubMed Web of Science ®Google Scholar
• Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009;32(Suppl2):S151-S6
   Web of Science ®Google Scholar
• Gerich J. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Med 2010;27:136-42
   PubMed Web of Science ®Google Scholar
• Whaley JM, Tirmenstein MR, Timothy P, et al. Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes 2012;5:135-48
   PubMedGoogle Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metabol 2011;97:1020-31
   Web of Science ®Google Scholar
• Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metabol 2014;16:159-69
   PubMed Web of Science ®Google Scholar
• Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial. Diabetes Obes Metabol 2011;13:928-38
   PubMed Web of Science ®Google Scholar
• Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156:405-15
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metabol 2014;16:124-36
   PubMed Web of Science ®Google Scholar
• Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial. Diabetes Obes Metabol 2013;15:432-40
   PubMed Web of Science ®Google Scholar
• Kaku K, Kiyosue A, Inoue S, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metabol 2014;16:1102-10
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-24
   PubMed Web of Science ®Google Scholar
• Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446-56
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, et al. Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Vico M, Wei LI, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8
   PubMed Web of Science ®Google Scholar
• Nauck M, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22
   PubMed Web of Science ®Google Scholar
• Aylsworth A. Dean Z, VanNorman C. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740-50
   PubMed Web of Science ®Google Scholar
• Yang L, Li H, Li H. Pharmacokinetic and pharmacodynamic properties of single-and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Therapeut 2013;35:1211-22.e2
   PubMed Web of Science ®Google Scholar
• Ji L, Lu J, Weng J, et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. Journal of diabetes, 7, 166-173
   Google Scholar
• Massi-Benedetti M. Glimerpiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Therapeut 2003;25:799-816
   PubMed Web of Science ®Google Scholar
• Langtly H, Balfour JA. Glimepiride, a review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84
   PubMed Web of Science ®Google Scholar
• Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-52
   PubMed Web of Science ®Google Scholar
• Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997;20:735-44
   PubMed Web of Science ®Google Scholar
• Mount H. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007;30:1638
   PubMed Web of Science ®Google Scholar
• Palmer AJ., Roze S, Valentine WJ. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood challenge meeting. Value Health 2013;16:670-85
   PubMed Web of Science ®Google Scholar
• Deng J, Gu S, Shao H, et al. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with type 2 diabetes mellitus inadequately controlled by oral therapies. J Med Econ 2015;18:974-89
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747-59
   PubMed Web of Science ®Google Scholar
• China Minister of Health. Chinese Health Statistics Yearbook. Beijing, 2013
   Google Scholar
• World Health Organization. The world health report 2002 – Chapter 5 (some strategies to reduce risk – technical considerations for cost-effectiveness analysis). 2002. Available at: http://www.who.int/whr/2002/en/Chapter5.pdf?ua¼1 [Last accessed 16 August 2015]
   Google Scholar
• Ji L, Ma JH, Li HM, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Therapeut 2014;36:84-100.e9
   PubMed Web of Science ®Google Scholar
• Bautista JL, Bugos C, Dirnberger G, et al. Efficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Therapeut 2003;25:194-209
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Holvey SM, Schneider J, et al. A dose–response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:849-56
   PubMed Web of Science ®Google Scholar
• Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211) a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004;27:1335-42
   PubMed Web of Science ®Google Scholar
• Nandy D, Johnson C, Basu R, et al. The effect of liraglutide on endothelial function in patients with type 2 diabetes. Diabetes Vas Dis Res 2014;11:419-30
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Debruin TW, et al. Dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension. Diabetes 2012;61(Suppl1):A271
   Web of Science ®Google Scholar
• Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003;22:35-43
   PubMed Web of Science ®Google Scholar
• Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009;8:573-84
   PubMed Web of Science ®Google Scholar
• Nauck M, Del P, Meier S, et al. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. Deutsche Medizinische Wochenschrift (1946) 2013;138:S6-S15
   PubMed Web of Science ®Google Scholar
• Price Bureau of China Official drug price list. 2014. Available at: http://www.zjpi.gov.cn/main/html/2013/CT10138/75fbbde9c06b496aba6490646b9ca77f.html April 2, 2016
   Google Scholar
• Gao L, Zhao F-L, Li S-C. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care 2012;28:436-44
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wu J, Xie K. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus (T2DM). Chinese Rural Health Service Admin 2012;32:1195-8
   Google Scholar
• Meng H. Pharmacoeconomic analysis of the treatment of type 2 diabetes complicated with urinary infections with two different antibiotics. J Shandong Med College 2009;31:91-3
   Google Scholar
• Worldwide Inflation Data. Historic inflation China. Available at: http://www.inflation.eu/inflation-rates/china/historic-inflation/cpi-inflation-china.aspx [Last accessed 3 August 2016]
   Google Scholar
• Guo H, Li J, Jiang Z. Follow-up effects of the increased physical activity on the glucolipid metabolic factors and medical costs in type 2 diabetic patients. Chinese J Rehab Med 2007;22:395-8
   Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decision Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan C, Li P, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
   PubMed Web of Science ®Google Scholar
• Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost–utility analysis of office-based strategies. J Urol 1998;159:1418-19
   Google Scholar
• China GDP. 2014. Available at: http://data.stats.gov.cn/easyquery.htm?cn=C01&zb=A0201&sj =2014 April 2, 2016
   Google Scholar
• Wilding JP, Woo V, Soler NG, et al. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]. Deutsche Medizinische Wochenschrift (1946) 2013;138:S27-S38
   PubMed Web of Science ®Google Scholar
• Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014;30:1267-73
   PubMed Web of Science ®Google Scholar
• Vivian EM. Dapagliflozin: a new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm 2015;72:361-72
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Merovci A, Solis-Herrera C, et al. Plasma glucose reduction with the SGLT2 inhibitor, dapagliflozin, improves insulin sensitivity and insulin secretion in T2DM. In: Diabetes. Alexandria, VA, USA: American Diabetes Association, 2013
   Google Scholar
• Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31:150-3
   PubMed Web of Science ®Google Scholar
• Biondi-Zoccai G, Agostoni P, Abbat A, et al. A simple hint to improve Robinson and Dickersin’s highly sensitive PubMed search strategy for controlled clinical trials. Int J Epidemiol 2005;34:224-5; author reply 225
   PubMed Web of Science ®Google Scholar
• Sterne JA, Bradburn MJ, Egger M. Meta-Analysis in Stata. Systematic Reviews in Health Care: Meta-Analysis in Context, 2nd edn. BMJ Books, 2008:347-69
   Google Scholar
• Ji L, Hu D, Pan C, et al. Primacy of the 3B approach to control risk factors for cardiovascular disease in type 2 diabetes patients. Am J Med 2013;126:925.e11-22
   PubMed Web of Science ®Google Scholar
• Li H, Xu F, Wang F. Cost-effectiveness of biphasic insulin aspart 30 combined with metformin in patients with type 2 diabetes mellitus. Chinese J New Drugs 2011;20:2163-70
   Google Scholar
• Palmer JL, Gibbs M, Scheijbeler HW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther 2008;25:752-74
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wu J, Xie K. Incidence and cost of hypoglycemia episode in patients with type 2 diabetes mellitus. Chinese Rural Health Servic Administration 2012:1195-8
   Google Scholar
• Craig CJ, Phil M, John P, et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value in Health 2005;8:581-90
   PubMed Web of Science ®Google Scholar
• Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality Life Res 2007;16:1251-65
   PubMed Web of Science ®Google Scholar
• Currie CJ, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
   PubMed Web of Science ®Google Scholar
• Jaime Caro J, Ozer Stillman I, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007;10:239-54
   Google Scholar